# A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

> **NCT00758043** · PHASE3 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 540 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** telaprevir
- **DRUG:** ribavirin
- **BIOLOGICAL:** peginterferon alfa-2a

## Key facts

- **NCT ID:** NCT00758043
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2010-06
- **Final completion:** 2010-07
- **Target enrollment:** 540 (ACTUAL)
- **Last updated:** 2021-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00758043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00758043, "A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00758043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*